Neurogene completes dosing in pivotal Rett syndrome gene therapy trial
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
Neurogene finished administering NGN-401 to all patients in its EmboldenTM registrational trial for Rett syndrome, a critical milestone moving the gene therapy candidate closer to potential regulatory submission.
Item 8.01 view on EDGAR → -
medium
The company posted an updated corporate presentation on its website, likely reflecting the trial milestone and providing strategic context for investors.
Item 8.01 view on EDGAR →
See the full narrative summary and section-by-section diff — create a free account to read more. Takes 30 seconds.
Partner
Trade NGNE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 9, 2026 3:44 PM